Reports related to this article:
Plant(s): View 3 related plants in PECWeb
Released March 26, 2019 | SUGAR LAND
en
Off the heels of purchasing Patheon in 2017, Thermo Fisher is acquiring Brammer Bio, a viral vector contract development and manufacturing organization (CDMO) for gene therapy innovators, for $1.7 billion.
Brammer Bio has a 66,000-square-foot Phase III and commercial CGMP viral vector manufacturing site in Cambridge, Massachusetts; a 49,000-square-foot warehouse and distribution center in Somerville, Massachusetts; an 80,000-square-foot early clinical campus in Alachua, Florida, consisting of three buildings; a process development and analytical development facility, next to its CGMP Phase I/II clinical manufacturing operation, with a third warehouse and office building; and a 50,000 square-foot viral vector manufacturing facility in Lexington, Massachusetts.
The purchase is expected to close by the end of the second quarter of 2019.
Brammer Bio has a 66,000-square-foot Phase III and commercial CGMP viral vector manufacturing site in Cambridge, Massachusetts; a 49,000-square-foot warehouse and distribution center in Somerville, Massachusetts; an 80,000-square-foot early clinical campus in Alachua, Florida, consisting of three buildings; a process development and analytical development facility, next to its CGMP Phase I/II clinical manufacturing operation, with a third warehouse and office building; and a 50,000 square-foot viral vector manufacturing facility in Lexington, Massachusetts.
The purchase is expected to close by the end of the second quarter of 2019.
